Remidio Showcases India's AI Eye Care Wins Globally at India AI Impact Summit 2026

New Delhi, India – Remidio Innovative Solutions, India's top AI medical imaging firm, will highlight its game-changing eye technology at the India AI Impact Summit 2026. The display

shows how homegrown innovation fights blindness on a massive scale and gears up to reshape healthcare worldwide.

Remidio has screened 16 million people in over 55 countries, with 1.3 million AI checks. Last year alone, it saved 80,000 from blindness and slashed screening costs by 97%, from ₹2,000 to just ₹60 per test. The company will shine at key summit spots: the main MeitY Pavilion, Odisha State Pavilion, Andhra Pradesh State Pavilion, and Summit Expo.

This strong presence across government pavilions reflects deep trust from partners. It's proof of Indian tech tackling world challenges – reliable AI set to grow from India outward.

Proven Results Across India
Remidio's AI runs in five states: Kerala, Pondicherry, Andhra Pradesh, Odisha, and Tamil Nadu. Top hospitals like AIIMS, Apollo Hospitals, LV Prasad Eye Institute, Dr. Mohan's Diabetes Specialities Centre, and Aravind Eye Hospital use it.

A massive real-world test, published in The Lancet Digital Health and checked by NHS UK, ranked Remidio tops. It compared eight AI systems on over 200,000 patient visits and 1.2 million retinal images for accuracy and reliability.

Only Certified 3-in-1 AI Tool
Remidio stands alone as the CDSCO- and CE-approved system spotting three big blindness causes – diabetic retinopathy, glaucoma, and age-related macular degeneration – in one scan. It meets ABDM, HIPAA, and GDPR rules, ready for India's health network and global use.

Pushing Oculomics for Preventive Care
Remidio leads in Oculomics, using eye scans to spot early signs of heart disease, kidney issues, anemia, brain decline, and pregnancy risks. It turns simple eye checks into full health insights, shifting to prediction and prevention at scale.

Find Remidio at the Summit
Stop by these spots to try the tech:

• MeitY Pavilion (Main Exhibition Hall)

• Odisha State Pavilion

• Andhra Pradesh State Pavilion

• Summit Expo Floor

About Remidio
Today, the human eye is unlocking early insights into systemic health, and Remidio is at the forefront of this transformation. Remidio is a pioneer in AI-driven eye care, leading the shift from care of the eye to healthcare through the eye. As the first company to receive CDSCO approval in India for our adaptive ophthalmic AI, in addition to CE marking in Europe under Class II EU-MDR, we are redefining how diseases like diabetic retinopathy, glaucoma, and AMD are detected early, in close to patient contexts, while remaining confident of extending this to systemic disease detection such as CVD, CKD and liver diseases, in the future.

With CE-marked, FDA 510(k)-registered devices, our solutions have screened 16 million+ patients across 55 countries, integrating teleophthalmology and AI for fast, accurate diagnoses. Our innovative retinal imaging solutions ensure precision and efficiency in clinical workflows.
Our journey began humbly - thanks to the chance meeting of our founder, with a mission driven ophthalmologist, who brought into focus the need for decentralizing eye testing with simple to use and affordable devices. That conversation, 15 years back, sparked a vision to make high-quality preventive care accessible to all.
Guided by innovation, empathy, and a commitment to global impact, our journey is just beginning!

---